ESMO 2024 | Addressing the impact of neoadjuvant treatment for MIBC in the NIAGARA trial
Alexandra Drakaki, MD, PhD, University of California Los Angeles, Los Angeles, CA, comments on the Phase III NIAGARA trial (NCT03732677), the first neoadjuvant study combining durvalumab with standard chemotherapy (cisplatin-gemcitabine) for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). This groundbreaking trial explores the use of immunotherapy alongside chemotherapy prior to surgery, followed by a year of single-agent immunotherapy post-operatively. The findings are expected to significantly influence surgical outcomes and overall survival (OS), marking a pivotal change in clinical practice for bladder cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
